F-S Wang1,2,3, W-S Lian1,2, W-T Weng1,2, Y-C Sun1,2, H-J Ke1,2, Y-S Chen1,2, J-Y Ko4,5. 1. Department of Medical Research, Kaohisung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. 2. Core Laboratory for Phenomics and Diagnostics, Kaohisung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. 3. Graduate Institute of Clinical Medical Sciences, Chang Gung University College of Medicine, Kaohsiung, Taiwan. 4. Graduate Institute of Clinical Medical Sciences, Chang Gung University College of Medicine, Kaohsiung, Taiwan. kojy@cgmh.org.tw. 5. Department of Orthopedic Surgery, Kaohsiung Chang Gung Memorial Hospital, 123, Ta-Pei Road, Niao-Sung District, Kaohsiung, 83303, Taiwan. kojy@cgmh.org.tw.
Abstract
UNLABELLED: Increased neuropeptide Y (NPY) expression occurred in the glucocorticoid-induced osteoporotic skeleton. NPY knockout mice exhibited a minor response to the glucocorticoid-mediated exacerbation of bone accretion and fatty marrow pathogenesis. NPY deletion restored SITR1 signaling and enhanced PPARγ ubiquitination of bone tissue, an alternative strategy for ameliorating glucocorticoid-induced skeletal deterioration. INTRODUCTION: Glucocorticoid excess is observed to worsen the pathogenesis of osteoporosis and fatty marrow. This study was undertaken to investigate the contribution of neuropeptide Y (NPY) to glucocorticoid-induced bone loss and marrow adiposity. METHODS: NPY knockout and wild-type mice were administered methylprednisolone for four consecutive weeks. Bone mineral density, microarchitecture, and calcein-labeled mineral acquisition were quantified by μCT, dual energy X-ray absorptiometry, and histomorphometry. Expression of osteogenic and adipogenic markers and acetylation states of PPARγ were detected by RT-quantitative PCR, immunoprecipitation, and immunoblotting. RESULTS: High NPY levels were associated with glucocorticoid-induced trabecular bone deterioration and marrow fat accumulation. Mice lacking NPY had high bone mass concomitant with spacious trabecular and cortical bone microstructure. NPY deletion shielded skeletal tissues from the glucocorticoid-induced impediment of bone mass, trabecular morphometric characteristics, mineral accretion activity, and fatty marrow development. Ex vivo, NPY deficiency sustained osteogenic differentiation capacity and curtailed the glucocorticoid-mediated escalation of adipocyte formation reactions of primary bone-marrow mesenchymal cells. NPY deletion appeared to modulate Y1 and Y2 receptors, sirtuin 1, ERK, and p38 signaling pathways, an effect that facilitated hypoacetylation and ubiquitination of adipogenic transcription factor PPARγ in the skeletal tissues exposed to glucocorticoid stress. CONCLUSIONS: NPY mediates the glucocorticoid-induced disturbance of mineral accretion and marrow adipogenesis through post-translational modification of PPARγ. This study brings a new molecular insight into the disintegration of adipogenic and osteogenic activities within glucocorticoid-mediated osteoporotic skeletons. Control of NPY is an alternative strategy to ameliorate glucocorticoid-induced bone destruction and fatty marrow.
UNLABELLED: Increased neuropeptide Y (NPY) expression occurred in the glucocorticoid-induced osteoporotic skeleton. NPY knockout mice exhibited a minor response to the glucocorticoid-mediated exacerbation of bone accretion and fatty marrow pathogenesis. NPY deletion restored SITR1 signaling and enhanced PPARγ ubiquitination of bone tissue, an alternative strategy for ameliorating glucocorticoid-induced skeletal deterioration. INTRODUCTION: Glucocorticoid excess is observed to worsen the pathogenesis of osteoporosis and fatty marrow. This study was undertaken to investigate the contribution of neuropeptide Y (NPY) to glucocorticoid-induced bone loss and marrow adiposity. METHODS:NPY knockout and wild-type mice were administered methylprednisolone for four consecutive weeks. Bone mineral density, microarchitecture, and calcein-labeled mineral acquisition were quantified by μCT, dual energy X-ray absorptiometry, and histomorphometry. Expression of osteogenic and adipogenic markers and acetylation states of PPARγ were detected by RT-quantitative PCR, immunoprecipitation, and immunoblotting. RESULTS: High NPY levels were associated with glucocorticoid-induced trabecular bone deterioration and marrow fat accumulation. Mice lacking NPY had high bone mass concomitant with spacious trabecular and cortical bone microstructure. NPY deletion shielded skeletal tissues from the glucocorticoid-induced impediment of bone mass, trabecular morphometric characteristics, mineral accretion activity, and fatty marrow development. Ex vivo, NPY deficiency sustained osteogenic differentiation capacity and curtailed the glucocorticoid-mediated escalation of adipocyte formation reactions of primary bone-marrow mesenchymal cells. NPY deletion appeared to modulate Y1 and Y2 receptors, sirtuin 1, ERK, and p38 signaling pathways, an effect that facilitated hypoacetylation and ubiquitination of adipogenic transcription factor PPARγ in the skeletal tissues exposed to glucocorticoid stress. CONCLUSIONS:NPY mediates the glucocorticoid-induced disturbance of mineral accretion and marrow adipogenesis through post-translational modification of PPARγ. This study brings a new molecular insight into the disintegration of adipogenic and osteogenic activities within glucocorticoid-mediated osteoporotic skeletons. Control of NPY is an alternative strategy to ameliorate glucocorticoid-induced bone destruction and fatty marrow.
Entities:
Keywords:
Bone loss; Glucocorticoid; Marrow adiposity; Neuropeptide Y
Authors: Jing Zhang; Katherine J Motyl; Regina Irwin; Ormond A MacDougald; Robert A Britton; Laura R McCabe Journal: Endocrinology Date: 2015-07-02 Impact factor: 4.736
Authors: Sylvia Thiele; Nicole Ziegler; Elena Tsourdi; Karolien De Bosscher; Jan P Tuckermann; Lorenz C Hofbauer; Martina Rauner Journal: J Bone Miner Res Date: 2012-11 Impact factor: 6.741
Authors: Lea H Dib; M Teresa Ortega; Sherry D Fleming; Stephen K Chapes; Tonatiuh Melgarejo Journal: Endocrinology Date: 2013-12-20 Impact factor: 4.736
Authors: Alexander S Banks; Fiona E McAllister; João Paulo G Camporez; Peter-James H Zushin; Michael J Jurczak; Dina Laznik-Bogoslavski; Gerald I Shulman; Steven P Gygi; Bruce M Spiegelman Journal: Nature Date: 2014-11-17 Impact factor: 49.962
Authors: Petra Simic; Kayvan Zainabadi; Eric Bell; David B Sykes; Borja Saez; Sutada Lotinun; Roland Baron; David Scadden; Ernestina Schipani; Leonard Guarente Journal: EMBO Mol Med Date: 2013-01-30 Impact factor: 12.137
Authors: Rafael Mayoral; Olivia Osborn; Joanne McNelis; Andrew M Johnson; Da Young Oh; Cristina Llorente Izquierdo; Heekyung Chung; Pingping Li; Paqui G Traves; Gautam Bandyopadhyay; Ariane R Pessentheiner; Jachelle M Ofrecio; Joshua R Cook; Li Qiang; Domenico Accili; Jerrold M Olefsky Journal: Mol Metab Date: 2015-03-05 Impact factor: 8.568
Authors: Natalie K Y Wee; Benjamin P Sinder; Sanja Novak; Xi Wang; Chris Stoddard; Brya G Matthews; Ivo Kalajzic Journal: Neuropeptides Date: 2018-11-30 Impact factor: 3.286
Authors: Josefine Tratwal; Rossella Labella; Nathalie Bravenboer; Greet Kerckhofs; Eleni Douni; Erica L Scheller; Sammy Badr; Dimitrios C Karampinos; Sarah Beck-Cormier; Biagio Palmisano; Antonella Poloni; Maria J Moreno-Aliaga; Jackie Fretz; Matthew S Rodeheffer; Parastoo Boroumand; Clifford J Rosen; Mark C Horowitz; Bram C J van der Eerden; Annegreet G Veldhuis-Vlug; Olaia Naveiras Journal: Front Endocrinol (Lausanne) Date: 2020-02-28 Impact factor: 5.555
Authors: Natalie K Y Wee; Ivana Vrhovac Madunic; Tonci Ivanisevic; Benjamin P Sinder; Ivo Kalajzic Journal: J Musculoskelet Neuronal Interact Date: 2020-12-01 Impact factor: 1.864